SEC Form 4 · accession 0001209191-17-027908
Forte Biosciences, Inc. · FBRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Martin J Duvall
Officer — Chief Executive Officer · Director
Period of report
Apr 19, 2017
Accepted (ET)
Apr 21, 2017 · 5:39 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001419041
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Apr 19, 2017 | J | 3,571 | $10.00 | A | 3,571 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents the conversion of outstanding convertible promissory notes in the aggregate principal amount of $35,000, plus an aggregate of $714.39 accrued interest, into shares of the Issuer's common stock upon closing of the Issuer's initial public offering at a conversion price of $10.00 per share.